Cytokinetics (NASDAQ:CYTK) vs. Immunocore (NASDAQ:IMCR) Critical Review

Cytokinetics (NASDAQ:CYTK – Get Free Report) and Immunocore (NASDAQ:IMCR – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations and institutional ownership.

Profitability

This table compares Cytokinetics and Immunocore’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cytokinetics -686.63% N/A -48.26%
Immunocore -7.48% -7.96% -2.93%

Insider and Institutional Ownership

84.5% of Immunocore shares are held by institutional investors. 2.6% of Cytokinetics shares are held by company insiders. Comparatively, 10.1% of Immunocore shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Cytokinetics and Immunocore”s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cytokinetics $88.04 million 80.31 -$784.96 million ($6.04) -8.40
Immunocore $400.02 million 3.40 -$35.51 million ($0.65) -40.63

Immunocore has higher revenue and earnings than Cytokinetics. Immunocore is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations for Cytokinetics and Immunocore, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cytokinetics 1 1 19 0 2.86
Immunocore 2 3 6 1 2.50

Cytokinetics presently has a consensus price target of $106.50, indicating a potential upside of 109.82%. Immunocore has a consensus price target of $52.86, indicating a potential upside of 100.14%. Given Cytokinetics’ stronger consensus rating and higher possible upside, equities analysts plainly believe Cytokinetics is more favorable than Immunocore.

Risk and Volatility

Cytokinetics has a beta of 0.45, indicating that its stock price is 55% less volatile than the S&P 500. Comparatively, Immunocore has a beta of 0.82, indicating that its stock price is 18% less volatile than the S&P 500.

Summary

Immunocore beats Cytokinetics on 9 of the 15 factors compared between the two stocks.

About Cytokinetics

(Get Free Report)

Cytokinetics is a biopharmaceutical company focused on discovering and developing medicines that target the biology of muscle function. Its research centers on therapies for conditions involving impaired cardiac muscle performance. The company’s work includes aficamten, a cardiac myosin inhibitor developed for hypertrophic cardiomyopathy, and other drug candidates designed to affect muscle contraction. Cytokinetics conducts research and clinical development through programs that may involve patients and collaborators in multiple countries.

About Immunocore

(Get Free Report)

Immunocore is a biotechnology company that develops T cell receptor (TCR)-based medicines for cancer and other diseases. Its ImmTAX platform is designed to create therapies that direct the body’s T cells toward targets inside cells, including targets that may be difficult for conventional antibody treatments to reach. The company’s marketed medicine, KIMMTRAK (tebentafusp-tebn), is a TCR-based therapy approved in the United States and other markets for certain patients with unresectable or metastatic uveal melanoma.

Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter.